A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

被引：7
作者：
Eisner, Florian [1 ]
Pichler, Martin [1 ]
Goletz, Steffen [2 ]
Stoeger, Herbert [1 ]
Samonigg, Hellmut [1 ]
机构：
[1] Med Univ Graz, Dept Internal Med, Div Oncol, A-8036 Graz, Austria
[2] GLYCOTOPE GmbH, Berlin, Germany
来源：
JOURNAL OF CLINICAL PATHOLOGY | 2015年 / 68卷 / 12期
关键词：
POLYMORPHISMS; IRINOTECAN; THERAPY;
D O I：
10.1136/jclinpath-2015-202996
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：1044 / 1046
页数：3
相关论文
共 8 条
[1]   Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].
Bibeau, Frederic ;
Lopez-Crapez, Evelyne ;
Di Fiore, Frederic ;
Thezenas, Simon ;
Ychou, Marc ;
Blanchard, France ;
Lamy, Aude ;
Penault-Llorca, Frederique ;
Frebourg, Thierry ;
Michel, Pierre ;
Sabourin, Jean-Christophe ;
Boissiere-Michot, Florence .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129
[2]   Evolving treatment strategies for colorectal cancer: A critical review of current therapeutic options [J].
Damin, Daniel C. ;
Lazzaron, Anderson R. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (04) :877-887
[3]   Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies [J].
Lejeune, Julien ;
Thibault, Gilles ;
Ternant, David ;
Cartron, Guillaume ;
Watier, Herve ;
Ohresser, Marc .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5489-5491
[4]   The role of personalized medicine in metastatic colorectal cancer: an evolving landscape [J].
Moorcraft, Sing Yu ;
Smyth, Elizabeth C. ;
Cunningham, David .
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (05) :381-395
[5]   Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer [J].
Musolino, Antonino ;
Naldi, Nadia ;
Bortesi, Beatrice ;
Pezzuolo, Debora ;
Capelletti, Marzia ;
Missale, Gabriele ;
Laccabue, Diletta ;
Zerbini, Alessandro ;
Camisa, Roberta ;
Bisagni, Giancarlo ;
Neri, Tauro Maria ;
Ardizzoni, Andrea .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1789-1796
[6]   Low overexpression of HER-2/PPPNeu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin®) and irinotecan as therapy.: A phase II trial [J].
Ramanathan, RK ;
Hwang, JJ ;
Zmaboni, WC ;
Sinicrope, FA ;
Safran, H ;
Wong, MK ;
Earle, M ;
Brufsky, A ;
Evans, T ;
Troetschel, M ;
Walko, C ;
Day, R ;
Chen, HX ;
Finkelstein, S .
CANCER INVESTIGATION, 2004, 22 (06) :858-865
[7]   Cancer statistics, 2013 [J].
Siegel, Rebecca ;
Naishadham, Deepa ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2013, 63 (01) :11-30
[8]   Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma [J].
Venook, AP .
CANCER, 2005, 103 (12) :2435-2446
1